HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Advocates call for early integration of palliative care into cancer therapy
-
- Carbon ion radiotherapy found effective in controlling growth of spinal sarcomas
- FDA grants breakthrough therapy designation to two leukemia drugs
- BRAF status not associated with negative predictors for papillary thyroid cancer
- Cyclophosphamide plus busulfan improves survival after AML remission
- Bevacizumab plus capecitabine effective in older patients with metastatic colorectal cancer
- Guidelines recommend low-dose CT screening in high-risk populations
- APBI, WBI for early-stage breast cancer associated with similar 10-year outcomes
- Biennial mammogram may be effective for some women
-
- Calcium, vitamin D failed to halt BMD loss in breast cancer
- Edoxaban after initial heparin found noninferior to standard therapy
- Elevated micropapillary component increased recurrence risk in lung adenocarcinoma
- First-degree relatives identified as high risk for papillary thyroid cancer
- HCC treatment underutilized in the US
- High levels of ST2 associated with treatment resistance, death in GVHD
- Malignant nodules alter thyroid circadian clock
- Patients taking warfarin after TJA may experience higher rates of readmission, complications
-
- Radiofrequency, laser ablation similarly effective for treating small HCC nodules
- Rituximab plus epratuzumab effective in follicular lymphoma
- Surgery and cetuximab most effectively treated very high-risk CSCC
- Targeted cancer therapies significantly increased pruritus risk
- Ultrasound characteristics may predict thyroid cancer risk
- Ultrasound elastography accurately predicted thyroid malignancy
- USPSTF updates recommendation for breast cancer risk-reducing medications
- European Commission approves Tafinlar for metastatic melanoma
-
- Ramucirumab meets survival endpoints for gastric, not breast cancer
- Foundation honors physician scientist
- ASTRO adds four members to board of directors
- Aspirin’s benefits linked to HLA class I expression in colorectal cancer
- Harm from prostate cancer screening may outweigh potential benefits
- Sorafenib benefited patients with RAS, BRAF mutations
- Zelboraf linked to antitumor activity in BRAF-mutated papillary thyroid cancer
- 12-gene assay predicted risk for rectal cancer recurrence
-
- 70-gene signature predicted locoregional breast cancer recurrence
- Tumor biology may guide therapy for cancers of unknown primary site
- Chemotherapy agents, corticosteroids associated with hyperglycemia Lisa K. Lohr, PharmD, BCPS, BCOP